chromatographyonline10h
Characterizing Antibody-Drug Conjugates Using Mass Spectrometry
Scientists from the National Institutes for Food and Drug Control have characterized antibody-drug conjugates (ADCs) using ...
FiercePharma15h
AZ, Daiichi's Enhertu nabs 7th FDA nod, including in 'HER2-ultralow' use, in breast cancer first
Just 11 days after AstraZeneca and Daiichi Sankyo gained FDA approval | The FDA has cleared AstraZeneca and Daiichi Sankyo's ...
BioPharma Dive14h
Enhertu, with new OK, set to supplant chemo in HER2-low breast cancer
The clearance is a step forward in AstraZeneca and Daiichi Sankyo’s plan to position antibody-drug conjugates like Enhertu ...
The American Journal of Managed Care15h
Emerging Therapies Shine Hope on Small Cell Lung Cancer Treatment
Newer treatments target pathways like Delta-like ligand 3, poly-ADP-ribose polymerase, and histone deacetylase to address ...
pharmaphorum18h
Enhertu gets first okay for HER2-ultralow breast cancer
AstraZeneca and Daiichi Sankyo have claimed their seventh FDA approval for Enhertu, getting the go-ahead for the blockbuster drug as a second-line treatment for patients with HER2-low and ...
Healio14h
FDA expands Enhertu approval for breast cancer
The FDA expanded the approval of trastuzumab deruxtecan for treatment of breast cancer.The new indication applies to use of ...
AstraZeneca, Daiichi’s drug cleared for wider use in breast cancer patients in US
Astra is due to pay Daiichi US$175 million in milestones after the US approval, the companies said. Enhertu is cleared in the ...
Pfizer to Showcase Advancements Across Genitourinary Cancers at ASCO GU Cancers Symposium
Pfizer Inc. (NYSE: PFE) will present the latest results from its leading genitourinary (GU) portfolio at the American Society ...
PMLiVE17h
AstraZeneca/Daiichi Sankyo’s Enhertu granted FDA approval in breast cancer
AstraZeneca (AZ) and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved by the US Food and Drug ...
Technology is enabling more precise treatments for cancer patients
The age of targeted cancer therapies brings the potential for more treatment options, greater effectiveness and fewer side ...
The Pharma Letter16h
New approval brings Enhertu to earlier HR-positive treatment setting
AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the USA as the first HER2-directed ...
Astrazeneca Stock: FDA Approval Boosts Cancer Treatment Portfolio
With a market capitalization of €207.0 billion, AstraZeneca maintains its prominent position in the global pharmaceutical sector. The company's positive trajectory is further evidenced by a 4.29 ...